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applied, the injury determination should be based upon the same imports to
which an eventual measure would be applied.
In sum, these two cases show the kinds of problems arising from the
lack of clarity in some provisions of RTA's that are not consistently
established vis-A-vis the corresponding rules, disciplines, or obligations
existing at the multilateral level (WTO).
X. THE PHARMACEUTICAL INDUSTRY'S INTERSECTION
WITH BUSINESS AND GOVERNMENT

Shannon S. S. Herzfeld
Introduction by Stephen Powell
Shannon Herzfeld is one ofthe leading trade economists in Washington.
She now serves as Senior Vice President for International Affairs for the
Pharmaceutical Research and Manufacturers of America.
SHANNON HERZFELD

The Americas are very important to the U.S., and to our companies,
especially the pharmaceutical companies of America. These companies are
the makers of pills, of capsules, of injectables - those liquids that
unfortunately come into you sometimes through intravenous needles. But
we are really not in the pill business at all; we are really in the idea business.
To give you some context about our industry (which is important
because really the trade rules are about people like us), for every 15,000
compounds or molecules looked at in one of our labs, three become
medicines approved for human use, and one turns a profit. This process
takes twelve to fifteen years.
Let me restate these odds in a different way. Imagine if, as you
embarked on your career, you were handed a hundred textbooks. Each
textbook had 150 pages in it, and you were told that you could become a
lawyer if you passed the bar exam. Imagine that the bar exam consisted of
one question, and the subject of that question was located on three pages
buried in those 100 textbooks. Imagine that the answer consisted of one
line on one single page. Now I ask you, how many of you would have
chosen to roll the dice, and chosen to become lawyers with such harsh
odds? And how many of you would have said, no, thanks, I will stay at my
* Senior Vice President of International Affairs of the Pharmaceutical Research and
Manufacturers of America Washington, D.C.
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family business, or stay at the beach, or do something else? Well, in our
business it takes 15,000 compounds examined to make three medicines
approved for human use, and to make one which makes a profit.
It also takes roughly $500 million, and as I said, a dozen years of work,
to produce a single medicine. That is why we say we are in a very high-risk
industry. It is a very high-risk proposition. So next time you read about
some blockbuster drug making millions of dollars, I just want you to know
we are not all living on easy street, and sometimes it is a bit more complex.
I got involved in the pharmaceutical industry because I am interested in
those points of intersection between business and government, and frankly,
I do not know of a single industry where this happens more.
At the birth of our first ideas, governments are right there in the delivery
room, because, in order to identify our idea, we have to file a patent and
go down to the Patent Office. Welcome to the world of intellectual
property.
We need to ensure that our medicines are both safe and effective. This
involves clinical trials, first on the computer, then using animals, then
involving healthy people, and then involving people with disease.
Governments regulate every step of this process, to insure the citizenry is
safe. And that is an essential element, I would add, of sovereignty. The
results of these trials, which are quite costly to create, also deserve
intellectual property protection. Then we have a medicine, found to be safe
and effective, and now we need government approval again. This is because
governments around the world have to give us permission to sell, and in
many countries, governments not only give us that permission but they
dictate our price. And finally, governments determine how we can sell our
product, who we can sell it to, what we can say about our product, and
who we can say it to.
I challenge you again to find any industry where there is more
government intervention. These rules are there, by-and-large, for good
public purposes. But rules can be fair, or rules can be trade barriers in
disguise. We need rules which are fair, transparent, and do not hamper our
ability to sell safe and effective medicines merely because a local industry
has failed to stay modem. That is why we, the pharmaceutical industry,
have always been firm supporters of the GATT, and continue to be
supporters of the WTO.
At this point, I would like to echo the observations of Governor
MacKay, about the importance of recent attention, coming out of the
private sector as well as governments, to the issue of corruption and
bribery. In all of the points of intersection which I just outlined between
governments and our industry, there are opportunities for "interruption,"
shall I say, from those who would like bribes or have other corrupt interests
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in mind. This is wrong. And what the pharmaceutical industry has been
trying to build, is global acceptance, or at a minimum a global statement,
in the name of civil society, that public health ought to be a bribery-andcorruption-free zone. And to the extent that you in academia can help us
put forth that principle, I would welcome that.
Beyond that, we believe that trade is good, and that trade under a rulesbased system, is our goal. We believe that having trade rules, acknowledged
widely, is not only a stable path, but the only stable path towards
sustainable economic development.
I stand here and I say "trade is good" and I smile because in my 21-year
career, that has always been a given. But I, like some of my colleagues
here, were in Seattle, where there were those who felt that perhaps that
statement needed to be re-assessed.
For those of you who once took Economics 101, I ask you to remember
the very simple logic of David Ricardo nearly 200 years ago, who went on
to say to the people of Portugal and to the people of England, "if you just
swap your wine for your cloth, both of you end up better." There is a net
gain. Countries - their citizens, consumers, and workers-all prosper when
free trade is allowed. All suffer when free trade is hindered. The GATT,
and now its successor organization, was created with this in mind, and we
all know David Ricardo was onto something, because in the 50 years since
this system was established, the world has witnessed the most dramatic rise
in living standards in history. World output per person has risen 2% per
year over the past half-century. That is double the rate of increase in the
prior 100 years before the two world wars.
A quarter of global output now crosses borders, and this share is even
higher for the developing world, where almost 40% of GDP is traded. That
number for many of the countries of Latin America is even higher.
Trade is good for you; trade is good for me; trade is particularly good
for Latin America. The booming U.S. economy, enjoying its seventh year
of uninterrupted growth, has been an important element, allowing other
countries in this region, to enjoy sustained exports and enhanced output.
Our own North America merchandise import volume rose by 10.5% alone.
This is a good thing. This translates into jobs and economic development
in the exporting and the importing countries. I acknowledge, though, that
opening one's market, trading by the rules - particularly the WTO rules
- is not always easy. It has been painful for some industries and some
developing countries, including some in Latin America, as they have
amended their own internal structures to conform to the WTO. That is why
these rules have implementation phase-in periods. These structural
adjustments are needed for people to come into compliance, and they must
be made. There is really no viable alternative. Isolationism does not work;
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protectionism does not work. Trade works, and sustainable trade needs
mutually recognized rules.
As I noted early on, my industry, the pharmaceutical industry, is an idea
industry, so in that regard, we are very dependent upon the protections
provided for intellectual property in the WTO-TRIPS agreement. So let me
take a minute to just explain how we perceive this very important
agreement. We believe that TRIPS establishes transparent rules that give
a minimum level of protection for ideas through the patent system. It really
is not all that hard. A patent is really just a deal between an idea-maker and
a sovereign, where the government says, "I'll give you a period of market
exclusivity, if you make your knowledge public, and you put it to work."
That is all a patent is. Patents, though, are critical to our research and
development, because all modem pharmaceuticals are really ideas.
The TRIPS agreement establishes a twenty-year period of patent
protection for all products, without discrimination across fields of
technology. That, too, is important because it means that patents
appropriately apply to medicines.
In addition, TRIPS contains protections for the very sensitive data that
I talked about earlier - the clinical trials data - that we must submit to
the regulatory authorities for the purposes of obtaining marketing approval.
This protection, known as data exclusivity, is an independent protection. It
is independent of patents, and in many industrialized countries, we are
provided a five to ten-year window, where only the originator of the data
can rely upon that data. To us, this is quite valuable because it prevents a
copier company from taking unfair advantage of the clinical trials data
which we have developed at great expense.
Overall, though, these are the key protections that allow the R&D in our
industry to keep flowing. And this year PhRMA-member companies will
invest $26 billion in R&D.
The TRIPS agreement's protection for patents provides the important
safeguards we need for our high-risk, high-stakes pharmaceutical sector.
These investments ensure that there will be new cures tomorrow. And
without intellectual property protection, it simply would not happen.
Investment - the $26 billion that I just noted - would flow elsewhere.
We are all quite aware, as Secretary of State Harris described, about the
magic and the wonder of the "dotcoms" - the IT industry - where money
is being attracted.
That is a big competitor to our industry for investment money. Don't
misunderstand, I am a big fan of the dotcoms, but let me just say, all the
dotcoms in the world will not be of much use to me, or to you, or to your
loved ones, should you become sick.
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We need to keep R&D in the pharmaceutical pipeline. We need that to
continue for our collective good health, and those of the ones we love. We
all enjoy wonderful medicines today, but we all expect that there is going
to be more tomorrow. But this is not a certainty, especially since ideas our ideas - are relatively easy to steal. And sadly, some governments,
including some prominent ones in Latin America, have chosen the piracy
path, hoping that it will be a shortcut to economic development and public
health. It is neither. The unauthorized copying of a pharmaceutical product
is the theft of our ideas. It provides no long-term benefit to foster growth
of a dynamic sector, and it does not promote technology transfer.
Oftentimes, the copies that are made are not even very good copies, so the
short-term benefit is illusory as well.
Because of this, we must all be very cautious when asked to pursue false
compromises, like exempting large parts of the world from the rules of
intellectual property.
Let me state that again. Intellectual property rights are merely the
vehicles which allow an inventor to assert ownership over his or her own
idea. We can never let this discussion be falsely reduced to one of an issue
of North versus South, or rich versus poor. Nobody - nobody - has a
monopoly on good ideas, and to imply that this might be the case gives
legitimacy to a dangerous and false idea that elevates expediency over
sustainable development. It is the wrong development path.
The Nobel prize winner for chemistry this past year was won by an
Egyptian-born scientist, Ahmed Zewail. He developed his idea in America,
because he was unable to fully develop and protect his idea in his home
country. While this was good luck for America, this was not a good
economic development path for Egypt, and now they know that. One of the
recipients of this year's PhRMA's Discoverer's Award, Dr. Jiben
Chikrabadi, was born in India, but he had to come overseas to develop his
break-through medicine, which now gives productive life to people who
suffer from schizophrenia. He had to come here, because the U.S. and the
EU had intellectual property laws, and India did not.
I admit that sometimes this discussion gets complicated, because it is
true that capital markets are imperfect, and it is true that the apparatus, as
many of you know, for recording, and enforcing, and adjudicating
intellectual property claims, may be weak or ineffective. It is true that
investors all over the world need mentoring on how to develop an idea into
a product, and how to get that product to market.
But these are basic economic development issues, not shortfalls in the
intellectual property laws. Receiving mentoring and basic economic
development is where work needs to be done - not weakening intellectual
property laws or the other rules of the WTO.
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Novel ideas spring forth in Bogota, and in Managuajust as much as they
can in Paris and in L.A. Strong intelledtual property laws and nondiscriminatory access to markets are sound trade policy, sound economic
policy, and sound public health policy. And on this, from our perspective,
there is very little room to compromise.
XI. SUB-REGIONAL ECONOMIC INTEGRATION PROGRAMS
IN LATIN AMERICA

Thomas Andrew 0 'Keefe*
It is important to keep in mind, in addition to MERCOSUR, that there
are other sub-regional economic integration programs in Latin America that
have produced some very significant results.
Two of them are, of course, the Andean Community, which consists of
five countries: Bolivia, Peru, Ecuador, Colombia, Venezuela. The second
is the Central American Integration System, which also consists of five
countries, although there is a sixth one there that is always waiting in the
wings. Those are Costa Rica, Nicaragua, El Salvador, Guatemala, and
Honduras, and that sixth one, of course, is Panama.
The Andean Community today is a very imperfect customs union. It is
imperfect for many of the same reasons why the MERCOSUR is also a very
imperfect union. There is a common external tariff or CET. It is basically
a four tiered system that consists of four different percentage rates,
although there is a fifth one that is usually added, 0%, for certain capital
goods that are not produced in the Andean sub-region.
But the reason why the Andean Community is an imperfect custom
union is that the CET does not cover all products across the board. There
are exceptions. In addition, while the CET is fully adhered to by Venezuela
and Colombia, Ecuador has a number of exceptions. Peru right now is
completely excluded, and Bolivia has its own import duty system as well.
The Andean Community is also an imperfect customs union for a second
reason. The idea with a customs union is that when you pay the CET upon
entering the territory of the union - one of the states in the union - it
becomes nationalized and can then be circulated among the other member
states without having to pay the CET again. Like the MERCOSUR, the
Andean Community, unfortunately, has not been able to resolve the issue
of the distribution among member states of the money that is collected by

* President of Mercosur Consulting Group, Ltd., Washington, D.C. Author "Latin American
Trade Agreements" (Ardsley-on-Hudson, N.Y. Transnational Publishers, 1997).
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